Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for subject:(paclitaxel PTX ). Showing records 1 – 3 of 3 total matches.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters


Univerzitet u Beogradu

1. Podolski-Renić, Ana. 1980-. Uspostavljanje rezistentnih tumorskih ćelijskih linija kao modela za testiranje novih hemioterapeutika : molekularna karakterizacija rezistencije nastale dugotrajnim izlaganjem paklitakselu.

Degree: Biološki fakultet, 2014, Univerzitet u Beogradu

Molekularna onkologija - Kancerogeneza / Molecular oncology - Cancerogenesis

Glavni uzrok neuspeha hemioterapije u lečenju kancera je pojava višestruke (engl. „multi-drug“) rezistencije (MDR). Efikasnost paklitaksela (PTX) je često ograničena pojavom rezistencije. Cilj ove doktorske disertacije je bio ispitivanje molekularnih i fenotipskih promena u toku razvoja MDR-a indukovanih PTX-om kod ćelijskih linija humanog karcinoma debelog creva (DLD1) i glioblastoma (U87). Takođe je testirana upotrebljivost dobijenih MDR modela u evaluaciji četiri anti-kancer agensa. Kontinuirani tretman PTX-om doveo je do razvoja MDR-a kod obe ispitivane ćelijske linije koje su postale rezistentne na strukturno i funkcionalno različite hemioterapeutike. Nakon potvrde prisustva ukrštene rezistencije kod novouspostavljenih ćelijskih linija DLD1-TxR i U87-TxR, analizirana je ekspresija membranskih trasportera uključenih u razvoj MDR-a na nivou iRNK. Ćelije su imale povišen nivo ekspresije mdr1 gena i smanjen nivo ekspresije mrp1 gena. Prekomerna ekspresija P-glikoproteina (P-gp), koji kodira mdr1 gen, je uočena kod obe MDR ćelijske linije. Analiza na protočnom citofluorimetru je pokazala da je akumulacija Pgp supstrata (rodamina 123 i doksorubicina) kod DLD1-TxR i U87-TxR ćelija značajno manja u poređenju sa odgovarajućim parentalnim ćelijama, DLD1 i U87. Značajno smanjenje ekspresije gst-π gena i koncentracije glutationa (GSH) je uočeno kod U87- TxR ćelija. Sekrecija vaskularnog endotelijalnog faktora rasta (VEGF) je inhibirana u jednokratnom tretmanu kod ćelijskih linija karcinoma debelog creva i u kontinuiranom tretmanu kod ćelijske linije glioblastoma. Analiza ćelijskog ciklusa je pokazala da je jednokratni tretman PTX-om kod ćelijskih linija humanog karcinoma debelog creva praćen porastom subG0 faze, odnosno povećanjem procenta mrtvih ćelija, dok je kod ćelija glioblastoma došlo do umiranja tokom interfaze (G1, S ili G2). MDR tumorske ćelijske linije su stekle nove strukturne i numerićke hromozomske aberacije. Sticanje MDR fenotipa kod U87-TxR ćelija je praćeno smanjenem jednog nivoa ploidije. Takođe je uočen gubitak hromozomskog regiona 6q kod obe rezistentne ćelijske linije, kao i inaktivacija p53 tumor spresor gena kod U87-TxR ćelija i PTEN tumor supresor gena kod DLD1-TxR ćelija.

Advisors/Committee Members: Radović, Svetlana, 1958-.

Subjects/Keywords: Multi-drug resistance (MDR); paclitaxel (PTX); colon cancer; glioblastoma; P-glycoprotein; anti-cancer agents

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Podolski-Renić, A. 1. (2014). Uspostavljanje rezistentnih tumorskih ćelijskih linija kao modela za testiranje novih hemioterapeutika : molekularna karakterizacija rezistencije nastale dugotrajnim izlaganjem paklitakselu. (Thesis). Univerzitet u Beogradu. Retrieved from https://fedorabg.bg.ac.rs/fedora/get/o:7135/bdef:Content/get

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Podolski-Renić, Ana 1980-. “Uspostavljanje rezistentnih tumorskih ćelijskih linija kao modela za testiranje novih hemioterapeutika : molekularna karakterizacija rezistencije nastale dugotrajnim izlaganjem paklitakselu.” 2014. Thesis, Univerzitet u Beogradu. Accessed February 24, 2020. https://fedorabg.bg.ac.rs/fedora/get/o:7135/bdef:Content/get.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Podolski-Renić, Ana 1980-. “Uspostavljanje rezistentnih tumorskih ćelijskih linija kao modela za testiranje novih hemioterapeutika : molekularna karakterizacija rezistencije nastale dugotrajnim izlaganjem paklitakselu.” 2014. Web. 24 Feb 2020.

Vancouver:

Podolski-Renić A1. Uspostavljanje rezistentnih tumorskih ćelijskih linija kao modela za testiranje novih hemioterapeutika : molekularna karakterizacija rezistencije nastale dugotrajnim izlaganjem paklitakselu. [Internet] [Thesis]. Univerzitet u Beogradu; 2014. [cited 2020 Feb 24]. Available from: https://fedorabg.bg.ac.rs/fedora/get/o:7135/bdef:Content/get.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Podolski-Renić A1. Uspostavljanje rezistentnih tumorskih ćelijskih linija kao modela za testiranje novih hemioterapeutika : molekularna karakterizacija rezistencije nastale dugotrajnim izlaganjem paklitakselu. [Thesis]. Univerzitet u Beogradu; 2014. Available from: https://fedorabg.bg.ac.rs/fedora/get/o:7135/bdef:Content/get

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation


Univerzitet u Beogradu

2. Milošević, Zorica, 1985-. Uloga mTOR i MAPK signalnih puteva u rezistenciji karcinoma štitaste žlezde na hemioterapiju.

Degree: Biološki fakultet, 2016, Univerzitet u Beogradu

Molekularna onkologija - Kancerogeneza / Molecular oncology - Cancerogenesis

Kаrcinomi štitаste žlezde su nаjčešći mаligniteti endokrinog sistemа. Klаsifikаcijа ovih mаlignitetа je izvršenа nа osnovu njihovih histopаtoloških kаrаkteristikа nа pаpilаrni, folikulаrni medulаrni i аnаplаstični kаrcinom (ATC). Većinа karcinoma štitаste žlezde je dobro diferencirаnа i imа odličnu prognozu (pаpilаrni i folikulаrni), dok аnаplаstični kаrcinom predstаvljа аgresivni tip sа izrаzito lošom prognozom uprkos rаzličitim terаpijskim pristupimа u njegovom lečenju. Promene u PI3K/AKT/mTOR i RAS/MAPK/ERK signаlnim putevima su karakteristične za nastanak karcinoma štitaste žlezde, koji su urođeno rezistentni na klasičnu hemioterapiju. Upravo promene u аktivnosti PI3K/AKT/mTOR i RAS/MAPK/ERK signаlnih putevа mogu dovesti i do rezistencije nа klаsične hemioterаpeutike. Još jedan od mogućih uzroka neuspehа hemioterаpije je i pojаvа višestruke (engl. multi-drug, MDR) rezistencije. Najčešći uzrok MDR-a je povišena ekspresija P-gp i BCRP transportnih pumpi. Cilj ove studije je bio ispitivanje uloge ključnih komponenti PI3K/AKT/mTOR i RAS/MAPK/ERK signаlnih putevа u pаtogenezi i rezistenciji ATC. Analizirane su promene na genskom i proteinskom nivou u uzorcima pаcijenаtа obolelih od ovog tipa kаrcinomа, kao i efekat inhibicije komponenti signalnih puteva kod humanih ATC ćelijskih linija. Pored toga, ispitana je i uloga P-gp i BCRP pumpi u rezistenciji ATC. Pokazano je da su i PI3K/AKT/mTOR i RAS/MAPK/ERK signаlni putevi važni za genezu ATC, kao i da se pritom međusobno isključuju. NRAS onkogen i p53 tumor supresor su izmenjeni u ispitivanim tumorskim uzorcima sa visokom učestalošću. Najčešće je izmenjen NRAS gen što ukazuje na njegovu ključnu ulogu u razvoju ATC. Sve otkrivene mutacije u NRAS genu i dve mutacije u p53 genu su po prvi put prijavljene kod ATC. In vitro studije su pokazale da se inhibicijom komponenti RAS/MAPK/ERK i PI3K/AKT/mTOR signalnih puteva povećava senzitivnost humanih ATC ćelija na klasičnu hemioterapiju. Najefikasnijim se pokazao dvostruki mTOR inhibitor AZD2014, kako u pojedinačnim tretmanima tako i u kombinaciji sa paklitakselom (PTX) i doksorubicinom (DOX)...

Advisors/Committee Members: Stamenković-Radak, Marina, 1958-.

Subjects/Keywords: Anaplastic thyroid cancer (ATC); RAS/MAPK/ERKpathway; PI3K/AKT/mTOR pathway; ATC chemoresistance; ATC invasiveness; dual mTOR inhibitor; AZD2014; paclitaxel (PTX)

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Milošević, Zorica, 1. (2016). Uloga mTOR i MAPK signalnih puteva u rezistenciji karcinoma štitaste žlezde na hemioterapiju. (Thesis). Univerzitet u Beogradu. Retrieved from https://fedorabg.bg.ac.rs/fedora/get/o:11053/bdef:Content/get

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Chicago Manual of Style (16th Edition):

Milošević, Zorica, 1985-. “Uloga mTOR i MAPK signalnih puteva u rezistenciji karcinoma štitaste žlezde na hemioterapiju.” 2016. Thesis, Univerzitet u Beogradu. Accessed February 24, 2020. https://fedorabg.bg.ac.rs/fedora/get/o:11053/bdef:Content/get.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

MLA Handbook (7th Edition):

Milošević, Zorica, 1985-. “Uloga mTOR i MAPK signalnih puteva u rezistenciji karcinoma štitaste žlezde na hemioterapiju.” 2016. Web. 24 Feb 2020.

Vancouver:

Milošević, Zorica 1. Uloga mTOR i MAPK signalnih puteva u rezistenciji karcinoma štitaste žlezde na hemioterapiju. [Internet] [Thesis]. Univerzitet u Beogradu; 2016. [cited 2020 Feb 24]. Available from: https://fedorabg.bg.ac.rs/fedora/get/o:11053/bdef:Content/get.

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

Council of Science Editors:

Milošević, Zorica 1. Uloga mTOR i MAPK signalnih puteva u rezistenciji karcinoma štitaste žlezde na hemioterapiju. [Thesis]. Univerzitet u Beogradu; 2016. Available from: https://fedorabg.bg.ac.rs/fedora/get/o:11053/bdef:Content/get

Note: this citation may be lacking information needed for this citation format:
Not specified: Masters Thesis or Doctoral Dissertation

3. Podolski-Renić Ana. The establishing of resistant cancer cell lines as a model for testing of new chemotherapeutics: molecular characterization of resistance developed after continuous treatment with paclitaxel.

Degree: PhD, Biology, 2013, University of Belgrade

Multi-drug resistance (MDR) is a major obstacle to successful cancer treatment. The efficacy of paclitaxel (PTX) is often limited by appearance of drug resistance. The aim of this study was to explore molecular and phenotypic alterations during development of MDR induced by PTX in human colon carcinoma (DLD1) and glioblastoma (U87) cell lines. We also tested the usefulness of developed MDR models in the evaluation of four anti-cancer agents. Continuous treatment with PTX led to the development of MDR in both tested cancer cell lines that became resistant to structurally and functionally unrelated chemotherapeutics. After confirmation of the cross-resistance in newly established DLD1-TxR and U87-TxR, we analyzed the mRNA expression of membrane transporters involved in MDR. The cells had increased levels of mdr1 gene expression, while mrp1 was decreased. Over-expression of P-glycoprotein (P-gp), coded by mdr1, was observed in both MDR cancer cell lines. Flow cytometry analyzes showed that the accumulation of P-gp substrates (rhodamine 123 and doxorubicin) in DLD1-TxR and U87-TxR was significantly lower compared to DLD1 and U87, respectively. The significant depletion of gst-π gene expression and glutathione (GSH) concentration was observed in U87-TxR. Vascular Endothelial Growth Factor (VEGF) secretion was inhibited by single PTX treatment of colon cancer and in continuous treatment of glioblastoma cell lines. The analysis of cell cycle kinetics revealed extensive cell death in colon cancer cells that were accumulated in subG0 phase after PTX treatment, while glioblastoma cells died through interphase (G1, S or G2). The MDR cancer cell lines acquired novel structural or numerical chromosomal aberrations. Polyploidy reduction was observed after development of MDR in U87-TxR. Losses of 6q in both resistant cancer cell lines and inactivation of p53 in U87-TxR and PTEN in DLD1-TxR were also revealed. We evaluated the anti-cancer activities and MDR reversal potential of the Akt inhibitor (GSK690693), the Ras inhibitor (Tipifarnib) and two P-gp inhibitors (jatrophane diterpenoids Euphodendrophane H-Euph H and Euphodendrophane S -Euph S). Their effects vary due to the cell-type differences, existence of MDR phenotype or tumor suppressors’ alterations. Tipifarnib, Euph H and S, significantly sensitized MDR cancer cells to PTX. In conclusion, continuous PTX treatment caused the over-expression of P-gp and acquisition of MDR in colon cancer and glioblastoma cell lines. MDR cancer cells obtained new molecular and cytogenetic characteristics, while some mechanisms of MDR and tumor progression such as GSH detoxification system and VEGF secretion were suppressed. The results implicate the PTX treatment as an important clinical tool for colon carcinoma and glioblastoma treatment even in the presence of MDR. Despite limitations discussed in literature due to the usefulness of MDR in vitro models, further examinations of changes provoked by artificially developed MDR are still emerging. Therefore, our MDR cancer cell lines present…

Subjects/Keywords: Multi-drug resistance (MDR); paclitaxel (PTX); colon cancer; glioblastoma; P-glycoprotein; anti-cancer agents; Višestruka (engl. „multi-drug“) rezistencija (MDR); paklitaksel (PTX); karcinom debelog creva; glioblastom; P-glikoprotein; anti-kancer agensi

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Ana, P. (2013). The establishing of resistant cancer cell lines as a model for testing of new chemotherapeutics: molecular characterization of resistance developed after continuous treatment with paclitaxel. (Doctoral Dissertation). University of Belgrade. Retrieved from http://dx.doi.org/10.2298/BG20130704PODOLSKIRENIC ; http://eteze.bg.ac.rs/application/showtheses?thesesId=804 ; https://fedorabg.bg.ac.rs/fedora/get/o:7135/bdef:Content/get ; http://vbs.rs/scripts/cobiss?command=SEARCH&base=99999&select=ID=1024577970

Chicago Manual of Style (16th Edition):

Ana, Podolski-Renić. “The establishing of resistant cancer cell lines as a model for testing of new chemotherapeutics: molecular characterization of resistance developed after continuous treatment with paclitaxel.” 2013. Doctoral Dissertation, University of Belgrade. Accessed February 24, 2020. http://dx.doi.org/10.2298/BG20130704PODOLSKIRENIC ; http://eteze.bg.ac.rs/application/showtheses?thesesId=804 ; https://fedorabg.bg.ac.rs/fedora/get/o:7135/bdef:Content/get ; http://vbs.rs/scripts/cobiss?command=SEARCH&base=99999&select=ID=1024577970.

MLA Handbook (7th Edition):

Ana, Podolski-Renić. “The establishing of resistant cancer cell lines as a model for testing of new chemotherapeutics: molecular characterization of resistance developed after continuous treatment with paclitaxel.” 2013. Web. 24 Feb 2020.

Vancouver:

Ana P. The establishing of resistant cancer cell lines as a model for testing of new chemotherapeutics: molecular characterization of resistance developed after continuous treatment with paclitaxel. [Internet] [Doctoral dissertation]. University of Belgrade; 2013. [cited 2020 Feb 24]. Available from: http://dx.doi.org/10.2298/BG20130704PODOLSKIRENIC ; http://eteze.bg.ac.rs/application/showtheses?thesesId=804 ; https://fedorabg.bg.ac.rs/fedora/get/o:7135/bdef:Content/get ; http://vbs.rs/scripts/cobiss?command=SEARCH&base=99999&select=ID=1024577970.

Council of Science Editors:

Ana P. The establishing of resistant cancer cell lines as a model for testing of new chemotherapeutics: molecular characterization of resistance developed after continuous treatment with paclitaxel. [Doctoral Dissertation]. University of Belgrade; 2013. Available from: http://dx.doi.org/10.2298/BG20130704PODOLSKIRENIC ; http://eteze.bg.ac.rs/application/showtheses?thesesId=804 ; https://fedorabg.bg.ac.rs/fedora/get/o:7135/bdef:Content/get ; http://vbs.rs/scripts/cobiss?command=SEARCH&base=99999&select=ID=1024577970

.